Characterization of an Engineered Src Kinase to Study Src Signaling and Biology

  • Leanna R. Gentry
  • Andrei V. Karginov
  • Klaus M. Hahn
  • Channing J. DerEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1360)


Pharmacologic inhibitors of protein kinases comprise the vast majority of approved signal transduction inhibitors for cancer treatment. An important facet of their clinical development is the identification of the key substrates critical for their driver role in cancer. One approach for substrate identification involves evaluating the phosphorylation events associated with stable expression of an activated protein kinase. Another involves genetic or pharmacologic inhibition of protein kinase expression or activity. However, both approaches are limited by the dynamic nature of signaling, complicating whether phosphorylation changes are primary or secondary activities of kinase function. We have developed rapamycin-regulated (RapR) protein kinases as molecular tools that allow for the study of spatiotemporal regulation of signaling. Here we describe the application of this technology to the Src tyrosine kinase and oncoprotein (RapR-Src). We describe how to achieve stable expression of this tool in cell lines and how to subsequently activate the tool and determine its function in signaling and morphology.

Key words

FK506-binding protein KRAS mTOR Oncogene Pancreatic cancer Rapamycin Src Tyrosine kinase 



This work was supported, in whole or in part, by National Institutes of Health Grants CA042978 to C.J.D. and CA175747 to C. J. D. and K. M. H.


  1. 1.
    Druker BJ (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1:31–36CrossRefPubMedGoogle Scholar
  2. 2.
    Karginov AV, Ding F, Kota P et al (2010) Engineered allosteric activation of kinases in living cells. Nat Biotechnol 28:743–747PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Gargalionis AN, Karamouzis MV, Papavassiliou AG (2014) The molecular rationale of Src inhibition in colorectal carcinomas. Int J Cancer 134:2019–2029CrossRefPubMedGoogle Scholar
  4. 4.
    Shields DJ, Murphy EA, Desgrosellier JS et al (2011) Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 30:2123–2134PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Cai H, Babic I, Wei X et al (2011) Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 71:862–872PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Chu PH, Tsygankov D, Berginski ME et al (2014) Engineered kinase activation reveals unique morphodynamic phenotypes and associated trafficking for Src family isoforms. Proc Natl Acad Sci U S A 111:12420–12425PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Dagliyan O, Shirvanyants D, Karginov AV et al (2013) Rational design of a ligand-controlled protein conformational switch. Proc Natl Acad Sci U S A 110:6800–6804PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Campbell PM, Groehler AL, Lee KM et al (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 67:2098–2106CrossRefPubMedGoogle Scholar
  9. 9.
    Radulovich N, Qian JY, Tsao MS (2008) Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol 439:1–13CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Leanna R. Gentry
    • 1
  • Andrei V. Karginov
    • 2
  • Klaus M. Hahn
    • 1
  • Channing J. Der
    • 1
    Email author
  1. 1.Department of PharmacologyUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Department of PharmacologyUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations